Shareholders challenge share swap at Genzyme Biosurgery
This article was originally published in Clinica
Executive Summary
Shareholders with a combined 15.6% of Genzyme Biosurgery's shares have filed a motion for a temporary injunction against Genzyme. They say that Genzyme officials played down the value of the biosurgery business in order to acquire its shares at a knock-down rate, and they want to block Genzyme's plan to eliminate Genzyme Biosurgery's Nasdaq-listed shares and exchange them for shares in Genzyme General.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.